Acurx Pharmaceuticals Files 8-K on Shareholder Votes

Ticker: ACXP · Form: 8-K · Filed: Jul 17, 2025 · CIK: 1736243

Sentiment: neutral

Topics: shareholder-vote, corporate-governance

Related Tickers: ACRX

TL;DR

ACRX filed an 8-K for shareholder votes on 7/17/25 - details to follow.

AI Summary

Acurx Pharmaceuticals, Inc. filed an 8-K on July 17, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the votes or outcomes, but it serves as a notification of such events.

Why It Matters

This filing indicates that Acurx Pharmaceuticals held a vote of its security holders, which could pertain to significant corporate actions or governance changes that may impact the company's future direction.

Risk Assessment

Risk Level: low — The filing is a procedural notification of a shareholder vote and does not disclose any immediate financial or operational risks.

Key Players & Entities

FAQ

What specific matters were submitted to a vote of Acurx Pharmaceuticals' security holders?

The provided 8-K filing does not specify the exact matters that were submitted for a vote by security holders.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on July 17, 2025.

What is the principal executive office address for Acurx Pharmaceuticals, Inc.?

The principal executive offices are located at 259 Liberty Avenue, Staten Island, NY 10305.

What is the IRS Employer Identification Number for Acurx Pharmaceuticals, Inc.?

The IRS Employer Identification Number for Acurx Pharmaceuticals, Inc. is 82-3733567.

What is the Standard Industrial Classification code for Acurx Pharmaceuticals, Inc.?

The Standard Industrial Classification code for Acurx Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 17, 2025 regarding Acurx Pharmaceuticals, Inc. (ACXP).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing